This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Peter Berger, MD

JAMA. 2004;291:365-367.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of THE JOURNAL, Chaitman and colleagues¹ report the results of the Combination Assessment of Ranolazine In Stable Angina (CARISA) trial, an important study evaluating ranolazine, a new antianginal drug. Ranolazine is the first member of a new class of drugs believed to reduce angina by partially inhibiting fatty acid oxidation, thereby increasing glucose oxidation and generating more ATP (adenosine triphosphate) per molecule of oxygen consumed.^2-3 In the Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) trial, an earlier placebo-controlled, double-blind trial of the same drug, ranolazine reduced angina and objective evidence of ischemia among patients who were taking no other antianginal medications.⁴ In CARISA, ranolazine reduced the frequency and severity of angina and improved exercise duration in patients with stable angina receiving other antianginal therapy, specifically those taking a standard dose of either atenolol, amlopidine, or diltiazem. This well-designed, well-conducted clinical trial in which . . . [Full Text of this Article]

Author Affiliations: Division of Cardiovascular Diseases, Duke University Medical Center, and Duke Clinical Research Institute, Durham, NC.

RELATED ARTICLE

Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic Angina: A Randomized Controlled Trial
Bernard R. Chaitman, Carl J. Pepine, John O. Parker, Jaroslav Skopal, Galina Chumakova, Jerzy Kuch, Whedy Wang, Sandra L. Skettino, and Andrew A. Wolff
JAMA. 2004;291(3):309-316.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ranolazine for Severe Chronic Angina?
Journal Watch Cardiology 2004;2004:3-3.
FULL TEXT  

Cardiovascular News
SoRelle
Circulation 2004;109 :e9004-e9005.
FULL TEXT